

INNOVATION VENTURES

**AVAILABLE TECHNOLOGIES** 

**CONTACT US** 

Request Information

Permalink

# Targeted Immunotherapy for Multiple Myeloma: Novel Mutant CCL27 Binders Targeting CCR10

Tech ID: 34320 / UC Case 2025-048-0

### **TECHNOLOGY DESCRIPTION**

Addressing the critical unmet need of resistance and relapse associated with current therapies, this innovative approach offers a powerful alternative to BCMA-targeted treatments. Our engineered CCL27 mutants exhibit significantly enhanced binding affinity to CCR10, enabling precise and effective targeting of cancer cells. Versatile in application, these binders can be utilized across a range of therapeutic platforms, including CAR Tcells and bispecific antibodies. Preclinical data demonstrates that mutant CCL27 CAR T cells exhibit superior cytotoxicity against multiple myeloma cell lines in vitro and significantly improved efficacy in vivo, outperforming BCMA-targeted therapies. This next-generation solution redefines possibilities for patients battling relapsed or resistant multiple myeloma.

## STAGE OF DEVELOPMENT

Pre-clinical proof of concept.

# RELATED MATERIALS

In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors -09/24/2025

#### **CONTACT**

Gemma E. Rooney

Gemma.Rooney@ucsf.edu tel: 415-625-9093.



# **OTHER INFORMATION**

**KEYWORDS** 

Multiple Myeloma, CART,

CCR10, CCL27, Binders,

**BCMA** 

### **CATEGORIZED AS**

- Medical
  - Disease: Cancer
  - Therapeutics

**RELATED CASES** 

2025-048-0

**ADDRESS UCSF** 

**Innovation Ventures** 

600 16th St. Genentech Hall, S-272.

San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax:

**CONNECT** 

Follow in Connect

© 2025, The Regents of the University of

California

Terms of use Privacy Notice